Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults ...
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and ...
Availability of the revised financial statements for Sanofi excluding Opella Paris, France – . Following the press release on October 21, 2024 and the plan to transfer a ...
Autoimmune type 1 diabetes (T1D) is an autoimmune progressive and lifelong condition that can develop regardless of age, lifestyle or family history. Individuals with autoimmune T1D are typically ...
Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd significantly improved progression-free survival, compared to standard-of-care VRd alone If approved, ...
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is ...
Although presymptomatic T1D (Stages 1 and 2) can be detected months or years before symptoms appear, most people are not diagnosed until they feel unwel. 10 11 Over the past 50 years, scientists ...
Ce communiqué contient des déclarations prospectives. Ces déclarations ne constituent pas des faits historiques. Ces déclarations comprennent des projections et des estimations ainsi que les ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback